Cortendo names new chair
This article was originally published in Scrip
Executive Summary
Cortendo, a global biopharmaceutical company focused on orphan endocrine disorders, has appointed John H Johnson chair of its board of directors and named Richard Kollender a director. These appointments, proposed by the nomination committee, were approved by shareholders during the Extraordinary General Meeting on 17 March. Mr Johnson has more than 30 years of biopharmaceutical industry experience at organizations including Johnson & Johnson, Lilly, ImClone and Pfizer. He is currently a member of the board of directors of Cempra Pharmaceuticals, Histogenics, Portola Pharmaceuticals, and Sucampo Pharmaceuticals. He previously served as chair of Dendreon and Tranzyme Pharma, and also served as a member of the board of directors of Pharmaceutical Research and Manufacturers of America (PhRMA), the Health Section Governing Board of Biotechnology Industry Organizations (BIO), and BioNJ.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.